Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F15%3AE0104854" target="_blank" >RIV/00843989:_____/15:E0104854 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.2217/IMT.15.30" target="_blank" >http://dx.doi.org/10.2217/IMT.15.30</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2217/IMT.15.30" target="_blank" >10.2217/IMT.15.30</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study
Popis výsledku v původním jazyce
Aim: To document the therapeutic efficacy and safety of Human Normal Immunoglobulin 10% Liquid (KIOVIG®/GAMMAGARD LIQUID® [IVIG 10%]) under clinical routine conditions. Patients & methods: Subjects received IVIG 10% according to the prescribing information and were followed for 6 +/- 1 weeks to 12 +/- 2 months depending on indication. Efficacy, adverse events, infusion rates and duration and dose were recorded. Results: Overall efficacy of IVIG 10% was rated as good or very good by the investigator in 81.8% of subjects; overall tolerability was good or very good in 87.5%. One serious adverse drug reaction (ADR) occurred (urticaria); no severe ADRs occurred. Conclusion: In this observational study, the efficacy and safety of IVIG 10% in routine clinical practice was similar to that previously reported in clinical studies.
Název v anglickém jazyce
Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study
Popis výsledku anglicky
Aim: To document the therapeutic efficacy and safety of Human Normal Immunoglobulin 10% Liquid (KIOVIG®/GAMMAGARD LIQUID® [IVIG 10%]) under clinical routine conditions. Patients & methods: Subjects received IVIG 10% according to the prescribing information and were followed for 6 +/- 1 weeks to 12 +/- 2 months depending on indication. Efficacy, adverse events, infusion rates and duration and dose were recorded. Results: Overall efficacy of IVIG 10% was rated as good or very good by the investigator in 81.8% of subjects; overall tolerability was good or very good in 87.5%. One serious adverse drug reaction (ADR) occurred (urticaria); no severe ADRs occurred. Conclusion: In this observational study, the efficacy and safety of IVIG 10% in routine clinical practice was similar to that previously reported in clinical studies.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
EC - Imunologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Immunotherapy
ISSN
1750-743X
e-ISSN
—
Svazek periodika
7
Číslo periodika v rámci svazku
n. 7
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
11
Strana od-do
"p. 753-763"
Kód UT WoS článku
000361669400006
EID výsledku v databázi Scopus
—